Goodwin’s Life Sciences team advised SetPoint Medical in its $30 million Series D equity financing which will enable the company to further advance the clinical development of its bioelectronic therapy for chronic, debilitating inflammatory diseases.
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative treatment for rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy.
The Goodwin team was led by partner included partner Kingsley Taft.
For additional details on the financing, please read the press release.